March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
TRAIL Influences Human Lymphatic Microvascular Endothelial Cell (HMVECs) Proliferation and Lymphangiogenesis
Author Affiliations & Notes
  • Birgit Regenfuss
    Ophthalmology, University of Cologne, Cologne, Germany
  • Deniz Hos
    Ophthalmology, University of Cologne, Cologne, Germany
  • Felix Bock
    Ophthalmology, University of Cologne, Cologne, Germany
  • Jasmine Onderka
    Ophthalmology, University of Erlangen-Nuremberg, Erlangen, Germany
  • Sharmila Masli
    Ophthalmology/Harvard Med School, Schepens Eye Research Institute, Boston, Massachusetts
  • Claus Cursiefen
    Ophthalmology, University of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships  Birgit Regenfuss, None; Deniz Hos, None; Felix Bock, None; Jasmine Onderka, None; Sharmila Masli, None; Claus Cursiefen, None
  • Footnotes
    Support  Interdisciplinary Center for Clinical Research (IZKF), DFG (German Research Foundation, SFB643, TP B10)
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2398. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Birgit Regenfuss, Deniz Hos, Felix Bock, Jasmine Onderka, Sharmila Masli, Claus Cursiefen; TRAIL Influences Human Lymphatic Microvascular Endothelial Cell (HMVECs) Proliferation and Lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2398. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Several (lymph-) angiogenic candidate genes were found to be differentially expressed between C57BL/6 and BALB/c or FVB mice with significantly more resting limbal vasculature in the former strain than the latter two. One of the candidate genes, TRAIL/Tnfsf10 was analyzed in greater detail to obtain insights into its effect on lymphatic endothelial cells.

Methods: : Corneal RNA was isolated and cDNA synthesis was carried out with SuperScriptTM III First-Strand Synthesis SuperMix. The cDNA was used for real-time PCR analyses. Lymphatic endothelial cell proliferation was analysed using BrdU incorporation into newly synthesized DNA. Surface expression of a corresponding death receptor of TRAIL (TRAIL-R2/DR5) was assessed by FACS analysis and immunocytochemistry.

Results: : Expression of TRAIL mRNA was increased 8.2-fold in BALB/c and 6.6-fold in FVB corneas compared to the C57BL/6 control corneas. This expression pattern corresponded with the decreased limbal vasculature in BALB/c and FVB compared to C57BL/6. Treatment of HMVECs with different concentrations of recombinant TRAIL in endothelial cell basal medium (containing 0.5 % FBS) resulted in a small, but significant inhibition of proliferation at a concentration of 1 ng/ml TRAIL. Flow cytometric analysis of surface expression of TRAIL-R2/DR5 (a corresponding death receptor of TRAIL) on HMVECs confirmed the presence of a ligand for TRAIL with an increased expression detectable after TNFα treatment (1 ng/ml and 100 ng/ml).

Conclusions: : Corneal expression of TRAIL may play an inhibitory role in lymphatic endothelial cell biology. Further studies are needed to clarify the detailed function of TRAIL in lymphangiogenesis.

Keywords: cornea: clinical science • inflammation • immune tolerance/privilege 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×